Spots Global Cancer Trial Database for Safety Study of MGAH22 in HER2-positive Carcinomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of MGAH22 in HER2-positive Carcinomas
Official Title: A Phase 1, Dose Escalation Study of MGAH22 in Patients With Refractory HER2 Positive Breast Cancer and Patients With Other HER2 Positive Carcinomas for Whom No Standard Therapy Is Available
Study ID: NCT01148849
Interventions
Study Description
Brief Summary: The purpose of this study is to determine if MGAH22 is safe when given by intravenous (IV) infusion to patients with HER2-positive cancer. The study will also evaluate how long MGAH22 stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it has an effect on tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
National Cancer Institute, Bethesda, Maryland, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Seoul National University Hospital, Seoul, , Korea, Republic of
Contact Details
Name: Stephen Eck, MD
Affiliation: MacroGenics
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
